Data protection Impressum

Pharma

Top Stories Western Switzerland

Business environment

Top Stories from Western Switzerland (May 2025)

28 May 2025

Western Switzerland is rapidly becoming a hotspot for biomanufacturing and life sciences companies, thanks to its strong infrastructure, skilled talent, and business-friendly policies. Yassin Nahi, GGBa (Greater Geneva Bern area) Life Science Director, shares how the region's research hubs, academic institutions, and regulatory support make it an ideal location for companies in this sector.

Why Western Switzerland for Biomanufacturing and Life Sciences Companies: an interview with expert Yassin Nahi

Lausanne-based biotech ReproNovo has secured USD 65 million to advance Phase 2 trials for novel therapies in male infertility and women’s reproductive health.

ReproNovo raises USD 65 million to advance trials in reproductive health

21 May 2025

HAYA Therapeutics, a precision medicine company based at Biopôle in Lausanne, has closed a USD 65 million Series A funding round to accelerate the clinical development of its RNA-guided therapies and expand its regulatory genome platform.

HAYA Therapeutics raises USD 65 million to advance RNA-guided therapies for chronic disease

12 May 2025

The latest edition of the Swiss Biotech Report underscores the continued growth and resilience of Switzerland’s biotech sector, attributing success to strong international collaborations and innovative advancements that promise to reshape healthcare worldwide.

The Swiss biotech industry: building resilience through global alliances

6 May 2025

From clinical research to international leadership, Incyte’s steady growth in Western Switzerland showcases the region’s strength in biopharmaceutical innovation.

Why Switzerland

Incyte, a key player in Western Switzerland’s biopharmaceutical innovation landscape

A team of researchers from the University of Bern and Japan’s RIKEN Institute has achieved a major breakthrough in sustainable chemistry by developing a novel method to synthesize organic molecules using sodium and iron—two abundant, non-toxic metals. The innovation could pave the way for more environmentally friendly production of pharmaceuticals and fine chemicals.

The University of Bern and RIKEN develop greener chemistry for pharmaceutical production

25 March 2025

The Lausanne University Hospital (CHUV) has secured market authorization from Swissmedic to produce a fecal microbiota transplant (FMT) medication, making it the first accredited center in Switzerland to manufacture this treatment under strict pharmaceutical standards. This breakthrough provides an effective solution for patients suffering from recurrent Clostridioides difficile infections, a debilitating condition characterized by repeated digestive blowouts and severe discomfort.

CHUV becomes first Swiss hospital to produce gut-balancing medication

29 January 2025

EPFL Innovation Park biotech company AB2 Bio has signed an option and licensing agreement with Japan-based Nippon Shinyaku to advance Tadekinig alfa, a novel treatment for Primary Monogenic IL-18 driven Hyperinflammatory Syndrome. The deal includes up to USD 36 million in early payments and milestone-based funding of up to USD 650 million.

AB2 Bio secures USD 650 million partnership with Nippon Shinyaku for rare disease therapy

27 January 2025

To meet the growing demand for hybrid expertise at the crossroads of life sciences and digital technologies, HES-SO Valais-Wallis has introduced a pioneering specialization in Digital Life Sciences, the first of its kind in Western Switzerland.

HES-SO introduces the first Digital Life Sciences program in Western Switzerland

10 December 2024

1 2 3 4 5 … 14